<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02742207</url>
  </required_header>
  <id_info>
    <org_study_id>HMO-15-0645</org_study_id>
    <nct_id>NCT02742207</nct_id>
  </id_info>
  <brief_title>Renal Function Post Cardioversion for Atrial Fibrillation</brief_title>
  <acronym>AFCARD-II</acronym>
  <official_title>Evaluation of Renal Function and Fluid Balance of Patient Undergoing Electrical Cardioversion for Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation is a common arrhythmia which requires electrical cardioversion in many
      patients in order to regain sinus rhythm. In a previous retrospective study a complication of
      acute renal failure was found in 17% of the patients after cardioversion.(The incidence and
      prognosis of renal dysfunction following cardioversion of atrial fibrillation. Helman
      Y,...Gilon D et al:Cardiology 2013;124(3);184-9.) Another complication previously described
      after cardioversion is pulmonary edema.

      In this prospective study the investigators aim to evaluate the risk of acute renal failure
      post cardioversion. In addition the investigators would like to evaluate hemodynamic changes,
      fluid balance and sodium levels in patients post cardioversion as a potential mechanism for
      both acute renal failure and pulmonary edema post cardioversion. In order to assess
      hemodynamic changes the investigators will use a non-invasive FDA approved device called
      NICaS (Non-Invasive Cardiac System). This system calculates cardiac output, cardiac index and
      peripheral vascular resistance in a non-invasive, fast and accurate way.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Renal dysfunction</measure>
    <time_frame>Short term - One month</time_frame>
    <description>Creatinine Clearance less 25 percent.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>One year</time_frame>
    <description>Death</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Renal Insufficiency</condition>
  <condition>Cardioversion</condition>
  <arm_group>
    <arm_group_label>Observational</arm_group_label>
    <description>All comers with Atrial fibrillation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <arm_group_label>Observational</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with new onset atrial fibrillation. Meaning less than three days.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients with new onset atrial fibrillation

        Exclusion Criteria:

          -  Pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <results_reference>
    <citation>Hellman Y, Cohen MJ, Leibowitz D, Loncar S, Gozal D, Haviv YS, Haber G, Afifi M, Rosenheck S, Lotan C, Pollak A, Gilon D. The incidence and prognosis of renal dysfunction following cardioversion of atrial fibrillation. Cardiology. 2013;124(3):184-9. doi: 10.1159/000346618. Epub 2013 Mar 9.</citation>
    <PMID>23485988</PMID>
  </results_reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2016</study_first_submitted>
  <study_first_submitted_qc>April 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2016</study_first_posted>
  <last_update_submitted>April 15, 2016</last_update_submitted>
  <last_update_submitted_qc>April 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hadassah Medical Organization</investigator_affiliation>
    <investigator_full_name>Dan Gilon</investigator_full_name>
    <investigator_title>Director, Non-Invasive Cardiology/Echocardiography</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

